JPRN-jRCT2080221733UnknownPhase 3
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis (STATURE)
ovartis Pharma K.K.0 sitesStarted: March 5, 2012Last updated:
Trial Snapshot
- Phase
- Phase 3
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 18age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •Subjects must have participated in the study CAIN457A2304 and have achieved a partial response after twelve weeks of treatment with no major protocol deviations.
- •A partial response is defined as having achieved >= PASI 50 but < 75 response.
Exclusion Criteria
- •-Forms of psoriasis other than chronic plaque -type
- •-Previous exposure to any biologic drug directly targeting IL-17 or the IL-17 receptor, except secukinumab in study CAIN457A2304
Investigators
Similar Trials
Completed
Phase 2
Comparison of two methods of administration of deferoxamine (intravenous and subcutaneous) in terms of impact on reducing iron overload in thalassemia patients who have suffered heart failure.Iron overload..Abnormal level of blood mineral.IRCT201206289827N2Kermanshah University of Medical Sciences and Health Services42
Not yet recruiting
Phase 4
Efficacy and Saftey of Intravenous Versus Oral Iron Therapy in Postpartum Anemia - A Randomised Controlled TrialCTRI/2020/02/023125Department of Obstetrics And Gynecology
Not yet recruiting
Phase 3
Comparison of efficacy and safety of two modes of Autologous Serum Therapy injectioCTRI/2024/02/062280Mythraye B
Not yet recruiting
Phase 4
Comparing Tramadol vs Paracetamol for Pain Relief in Acute Pancreatitis: A Randomized Controlled TrialCTRI/2024/06/068751DR ABHIJEET SHRIDHAR
Completed
Phase 2
Evaluating the effects of intravenous immunoglobulin (IVIG) in COVID-19 patientsIRCT20151227025726N20Shahid Beheshti University of Medical Sciences80